IonQ Earnings Call: Key Takeaways
IonQ delivered record Q2 revenue of $80.1M, up 287% YoY, while closing the $1.8B Skywater acquisition to become a vertically integrated quantum platform.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Filing type
Alerts
Time
2,575 alerts with these filters
IonQ delivered record Q2 revenue of $80.1M, up 287% YoY, while closing the $1.8B Skywater acquisition to become a vertically integrated quantum platform.
TTM Technologies announced a $400 million incremental investment to expand manufacturing capacity across four facilities in China and its facility in Penang, Malaysia. The expansion uses a "rapid-ramp" brownfield approach to scale advanced interconnect technology for AI data center infrastructure and hyperscalers. This investment is in addition to the company's previously disclosed $1.2 billion commitment for the 2025-2029 period.
Humana entered into a new strategic joint venture with BlackRock to manage and operate nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake held by Welsh, Carson, Anderson & Stowe (WCAS) for approximately $2.8 billion, providing Humana with a lower cost of capital and enhanced balance sheet efficiency by removing existing put option liabilities.
IonQ has entered into a definitive agreement to acquire Elisity, Inc., a Zero Trust security company, in an all-stock transaction valued at up to $1.3 billion including earnouts. The deal consists of $1.15 billion in closing consideration plus up to $150 million in revenue-based earnout consideration through January 2028. The acquisition aims to combine IonQ's quantum cryptography capabilities with Elisity's Zero Trust platform to address emerging quantum-era cybersecurity threats.
“With Elisity and its team as part of IonQ, we will be well positioned to help customers protect critical infrastructure and enterprise networks throughout the transition to the quantum era. As I said first, Q-Day is coming much faster than predicted. IonQ is offering its customers a vertically integrated full-stack quantum platform across quantum computing, networking, sensing and cybersecurity. Just as adding SkyWater Technology expanded IonQ’s capabilities in chip design, fabrication and packaging, Elisity will bring proven enterprise policy enforcement scale and deployment experience to our quantum security strategy and will give IonQ a strong growth platform to serve customers and create value for our shareholders.”
Niccolo de Masi, Chairman and CEO of IonQ
“Our customers need to prioritize post-quantum cryptography initiatives while securing existing assets to keep essential operations running. With IonQ, we will be optimally positioned to partner with them to modernize their crypto-agility programs, accelerate post-quantum cryptography capabilities while advancing their holistic Zero Trust posture and deploy hybrid-cybersecurity solutions today that are prepared for the quantum future.”
James Winebrenner, CEO of Elisity
Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.
ClearOne, Inc. received a staff determination letter from Nasdaq on October 8, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders' equity requirement. As a result, Nasdaq has determined to delist the company's common stock, though ClearOne intends to appeal this decision before a Nasdaq Hearings Panel to stay the delisting process.
Quetta Acquisition Corporation received a delisting notice from Nasdaq because it failed to complete an initial business combination within the required 36-month period following its IPO. Trading of the company's securities (QETA, QETAR, QETAU) will be suspended on October 14, 2026, and the company expects its securities to transition to the OTC Pink Limited Market.
Gentherm completed the acquisition of Modine Manufacturing Company's Performance Technologies business (SpinCo) through a merger transaction. Modine shareholders received 0.44619 shares of Gentherm common stock for each SpinCo share, resulting in Modine shareholders owning approximately 43.62% of the combined company. The deal establishes Gentherm as a scaled leader in thermal management and precision flow solutions.
Gran Tierra Energy stockholders approved the sale of the company's Colombian and Ecuadorian businesses to Maurel & Prom for approximately $1.33 billion. The company expects to receive $315 million in net cash proceeds and become debt-free upon the deal's expected closing by December 31, 2026.
Sunshine Biopharma Inc. closed a best efforts public offering of approximately 10.9 million units for gross proceeds of $6.0 million. Each unit, priced at $0.55, consists of one share of common stock (or a pre-funded warrant) and two Series D warrants. The company intends to use the net proceeds for general corporate purposes and working capital.
Flyte Aviation, Inc. entered into an agreement with existing investors to sell 2,050 shares of Series C-4 Convertible Preferred Stock for gross proceeds of $2.05 million. The preferred shares are convertible into common stock at a price of $1.00 per share. Additionally, the company reduced the conversion price of all outstanding Series C, Series D, and Series J preferred stock to $1.00 per share.
Streamex Corp. received a deficiency notice from Nasdaq on October 7, 2026, for failing to maintain the minimum bid price of $1.00 per share over 30 consecutive business days. The company has until April 5, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least ten consecutive business days. The notice does not have an immediate effect on the listing of the company's common stock (STEX).
Arrive AI Inc. closed a $250,000 private placement (PIPE) with an accredited investor, issuing 384,615 shares of common stock and warrants at a purchase price of $0.65 per unit. The investment was priced at a 213% premium to the company's recent trading price, and the investor expressed interest in evaluating up to $10 million in additional future financing.
Artelo Biosciences was identified as one of approximately 180 companies currently below Nasdaq's new $5 million minimum Market Value of Listed Securities (MVLS) requirement. While the rule is currently under a temporary stay and subject to proposed modifications, the company is monitoring the situation and considering potential actions to maintain compliance, such as capital raises or expense management.
Live Nation reports record demand with double-digit fan growth expected for 2026, driven by international expansion and a strong second-half concert slate.
Vivakor, Inc. has signed a non-binding Letter of Intent to acquire 100% of Direct Midstream, LLC for a gross purchase price of $40 million. The deal structure includes a $10 million capital investment by Vivakor, with the remaining consideration consisting of $29 million in Series B Preferred Stock and $1 million in common stock. The acquisition aims to expand Vivakor's Permian Basin infrastructure and oilfield waste management capabilities.
Crescent Energy Company priced an underwritten public offering of 80,000,000 shares of Class A Common Stock at $12.50 per share, with underwriters fully exercising their option for an additional 12,000,000 shares. The company expects to receive approximately $1,115.9 million in net proceeds, which will be used to fund the cash consideration for its acquisition of Eagle Ford assets from Devon Energy. KKR & Co. Inc. affiliates participated in the offering by purchasing 40,000,000 shares at the public offering price.
SINTX Technologies received approximately $2.01 million in gross proceeds from the exercise of Class B Common Stock Purchase Warrants. The company issued 651,204 shares of common stock and 290,219 pre-funded warrants at an exercise price of $2.14 per share, while unexercised Class B warrants expired.
DarkPulse, Inc. received notice that its common stock was removed from the OTCQB market and moved to the OTCID market effective October 8, 2026. The transition occurred because the company failed to maintain the minimum bid price requirement of $0.01 per share following the expiration of a grace period.
Selectis Health, Inc. completed its merger with Black Pearl Equities II, LLC, a subsidiary of Black Pearl Equities, LLC. Following a successful tender offer for approximately 90.93% of outstanding shares at $5.75 per share, the company merged with a subsidiary of the purchaser and became a wholly owned private subsidiary. The merger was effected under Utah law without a stockholder vote.
iSpecimen Inc. stockholders approved the acquisition of assets from Foldlab AI Ltd., which includes the issuance of common stock as partial consideration. The company also received approval for potential future equity issuances exceeding 19.99% of outstanding shares under Nasdaq rules, while the vote on a proposed reverse stock split was adjourned to October 30, 2026.
bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to raise approximately $4 million in gross proceeds. The offering consists of 116,545 shares of common stock and pre-funded warrants for 536,836 shares, priced at $6.122 and $6.115 respectively, alongside a private placement of unregistered warrants.
XMax Inc. entered into a definitive agreement to acquire 100% of Hexa Creation Inc. for approximately $4.12 million in cash. Hexa Creation is a developer of 1200V vertical gallium nitride (GaN) power semiconductor technology aimed at AI data center infrastructure. The deal expands XMax's strategic focus into high-voltage power semiconductors for AI computing and electric vehicles.
“This acquisition marks XMax’s entry into high-voltage power semiconductors, a field closely tied to the growing power demands of AI infrastructure. The acquisition of Hexa Creation diversifies our business opportunities and complements XMax’s growing AI business as XMax builds out AI software, platform-based and GPU services through our wholly owned subsidiaries XMax AI Inc. and Elonx AI Holdings PTE. LTD.”
Andy Lu, Chief Executive Officer of XMax
“We believe the acquisition by XMax would give our 1200V vertical GaN work a path toward commercialization. We believe vertical GaN can bring higher efficiency and power density to high-voltage applications, and XMax’s support allows us to focus on advancing that technology.”
Professor Yuji Zhao, CEO and Founder of Hexa Creation
Hepion Pharmaceuticals completed the acquisition of all issued and outstanding membership interests of Gravitas Life Sciences, LLC from Gravitas Collective Corp. The total consideration consisted of $2.0 million in cash, 25,000,000 shares of common stock valued at $2.25 million, and an additional $135,000 payment. The transaction is classified as a related party transaction as several Hepion directors are also officers of Gravitas Life Sciences.
Alpine Income Property Trust, Inc. entered into a definitive agreement to acquire a 13-property industrial portfolio across 11 states for $117.3 million. The company has made a $1.0 million non-refundable earnest money deposit and expects the closing of the acquisition to be probable.
Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2.5 million stockholders' equity requirement. The company intends to request a hearing before the Nasdaq Hearings Panel to stay the delisting and is currently evaluating strategic alternatives to regain compliance.
Ashford Hospitality Trust completed the sale of the 263-room Embassy Suites Philadelphia Airport hotel for approximately $26.0 million in cash. The company utilized approximately $24.6 million of the proceeds to pay down a mortgage loan secured by a 12-hotel portfolio. This transaction is part of the company's ongoing strategy to dispose of assets and reduce its outstanding indebtedness.
Evernorth Holdings Inc. (Pubco) completed its previously announced business combination with Pathfinder Digital Assets LLC, Ripple Labs Inc., and Arrington Capital SPAC I Inc. on October 9, 2026. In connection with the closing, SPAC shareholders redeemed approximately 18.46 million shares for $195.39 million in cash, representing 80.3% of eligible shares.
Better Home & Finance Holding Company received a deficiency notice from Nasdaq on October 8, 2026, for failing to meet multiple corporate governance requirements following recent board resignations. The company is currently non-compliant with rules requiring a majority of independent directors and independent oversight for its audit, compensation, and nominating committees. The company has 45 days to submit a plan to regain compliance, and the notice has no immediate effect on the listing of its Class A common stock (BETR).
Accendra Health received a deficiency notice from the NYSE on October 6, 2026, because its common stock average closing price fell below $1.00 over a 30 trading-day period. The company has six months to regain compliance and is considering alternatives including a potential reverse stock split. The notice does not immediately impact the listing or the company's business operations.